Incretin-based therapies in type 2 diabetes: A review of clinical results

Emanuele Bosi; Pietro Lucotti; Emanuela Setola; Lucilla Monti; Pier Marco Piatti

doi:10.1016/j.diabres.2008.10.003

Incretin-based therapies in type 2 diabetes: A review of clinical results

Emanuele Bosi, Pietro Lucotti, Emanuela Setola, Lucilla Monti, Pier Marco Piatti

Research output: Contribution to journal › Article › peer-review

Abstract

GLP-1 analogues (incretin mimetics) and DPP-4 inhibitors (incretin enhancers) represent new classes of anti-diabetic agents for the treatment of type 2 diabetes. The efficacy and safety of the incretin mimetic exenatide and of the DPP-4 inhibitors, sitagliptin and vildagliptin, have been clearly demonstrated by a very large number of clinical trials. Efficacy was demonstrated in terms of reduction of HbA1c, fasting and postprandial glucose. Moreover, exenatide showed a favourable effect on weight, while DPP-4 inhibitors were neutral with respect to this outcome. The low rate of hypoglycemic events seen in all studies confirms the glucose dependent action of incretins.

Original language	English
Journal	Diabetes Research and Clinical Practice
Volume	82
Issue number	SUPPL. 2
DOIs	https://doi.org/10.1016/j.diabres.2008.10.003
Publication status	Published - Dec 15 2008

Keywords

Diabetes mellitus
DPP-4 inhibitors
Exenatide
GLP-1 analogues
Sitagliptin
Vidagliptin

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Internal Medicine
Endocrinology

Access to Document

10.1016/j.diabres.2008.10.003

Fingerprint Dive into the research topics of 'Incretin-based therapies in type 2 diabetes: A review of clinical results'. Together they form a unique fingerprint.

Cite this

@article{b8c544cf6b8f44a5827623c24766f017,

title = "Incretin-based therapies in type 2 diabetes: A review of clinical results",

abstract = "GLP-1 analogues (incretin mimetics) and DPP-4 inhibitors (incretin enhancers) represent new classes of anti-diabetic agents for the treatment of type 2 diabetes. The efficacy and safety of the incretin mimetic exenatide and of the DPP-4 inhibitors, sitagliptin and vildagliptin, have been clearly demonstrated by a very large number of clinical trials. Efficacy was demonstrated in terms of reduction of HbA1c, fasting and postprandial glucose. Moreover, exenatide showed a favourable effect on weight, while DPP-4 inhibitors were neutral with respect to this outcome. The low rate of hypoglycemic events seen in all studies confirms the glucose dependent action of incretins.",

keywords = "Diabetes mellitus, DPP-4 inhibitors, Exenatide, GLP-1 analogues, Sitagliptin, Vidagliptin",

author = "Emanuele Bosi and Pietro Lucotti and Emanuela Setola and Lucilla Monti and Piatti, {Pier Marco}",

year = "2008",

month = dec,

day = "15",

doi = "10.1016/j.diabres.2008.10.003",

language = "English",

volume = "82",

journal = "Diabetes Research and Clinical Practice",

issn = "0168-8227",

publisher = "Elsevier Ireland Ltd",

number = "SUPPL. 2",

}

TY - JOUR

T1 - Incretin-based therapies in type 2 diabetes

T2 - A review of clinical results

AU - Bosi, Emanuele

AU - Lucotti, Pietro

AU - Setola, Emanuela

AU - Monti, Lucilla

AU - Piatti, Pier Marco

PY - 2008/12/15

Y1 - 2008/12/15

N2 - GLP-1 analogues (incretin mimetics) and DPP-4 inhibitors (incretin enhancers) represent new classes of anti-diabetic agents for the treatment of type 2 diabetes. The efficacy and safety of the incretin mimetic exenatide and of the DPP-4 inhibitors, sitagliptin and vildagliptin, have been clearly demonstrated by a very large number of clinical trials. Efficacy was demonstrated in terms of reduction of HbA1c, fasting and postprandial glucose. Moreover, exenatide showed a favourable effect on weight, while DPP-4 inhibitors were neutral with respect to this outcome. The low rate of hypoglycemic events seen in all studies confirms the glucose dependent action of incretins.

AB - GLP-1 analogues (incretin mimetics) and DPP-4 inhibitors (incretin enhancers) represent new classes of anti-diabetic agents for the treatment of type 2 diabetes. The efficacy and safety of the incretin mimetic exenatide and of the DPP-4 inhibitors, sitagliptin and vildagliptin, have been clearly demonstrated by a very large number of clinical trials. Efficacy was demonstrated in terms of reduction of HbA1c, fasting and postprandial glucose. Moreover, exenatide showed a favourable effect on weight, while DPP-4 inhibitors were neutral with respect to this outcome. The low rate of hypoglycemic events seen in all studies confirms the glucose dependent action of incretins.

KW - Diabetes mellitus

KW - DPP-4 inhibitors

KW - Exenatide

KW - GLP-1 analogues

KW - Sitagliptin

KW - Vidagliptin

UR - http://www.scopus.com/inward/record.url?scp=56949086428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56949086428&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2008.10.003

DO - 10.1016/j.diabres.2008.10.003

M3 - Article

C2 - 19022515

AN - SCOPUS:56949086428

VL - 82

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - SUPPL. 2

ER -